Abstracts tagged "rheumatoid arthritis"

Abstract Number: 460 • 2016 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models
Yohei Yoshiga¹, Fumihito Hosoi¹, Satoru Iguchi¹, Ryuusuke Kaneko¹, Yoshinori Nakachi¹, Daichi Akasaka¹, Kenji Tanaka², Kazuhiko Yonekura², Teruhiro Utsugi², Eiji Sasaki² and Yoshikazu Iwasawa², ¹TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, ²TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Bruton’s Tyrosine Kinase (BTK), a non-receptor tyrosine kinase is involved in intracellular signaling pathways downstream of several receptors, including the B cell receptor (BCR),…
Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 485 • 2016 ACR/ARHP Annual Meeting
Sexual Dimorphism of Popliteal Lymph Node Collapse As a Biomarker of Disease Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Emily Wu¹, Richard Bell², Christopher Rudmann³, Ronald Wood⁴, Christopher T. Ritchlin⁵, Homaira Rahimi⁶ and Edward Schwarz⁷, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, ⁴University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, ⁷Orthopedeatrics, University of Rochester, Rochester, NY
Background/Purpose: Although rheumatoid arthritis (RA) tends to occur earlier and with increased severity in females, the underling etiology of this sexual dimorphism is unknown. We…
Abstract Number: 3011 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Frank H.J. van den Hoogen^1,2, Jaap Fransen², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴, Aatke van der Maas¹ and Noortje van Herwaarden¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Long-term Outcomes After Disease Activity Guided Tapering of TNF Inhibitors in Rheumatoid Arthritis: 3 Year Data of a Randomized Controlled Pragmatic Non Inferiority Strategy Study…
Abstract Number: 497 • 2016 ACR/ARHP Annual Meeting
The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis
Josef Smolen¹, Roy Fleischmann², Daniel Aletaha³, Yihan Li⁴, Stefan Florentinus⁴ and Ivan Lagunes Galindo⁴, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Medical University Vienna and Hietzing Hospital, Vienna, Austria, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the American College of Rheumatology (ACR)20 score was developed to best discriminate effective from placebo…
Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting
The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study
Sheng-Xiao Zhang¹, Miao Miao², Xiao-Qing Liu², Xiao-Wen Ma², Xiao-Yan Wu² and Xiao-Feng Li¹, ¹Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…
Abstract Number: 575 • 2016 ACR/ARHP Annual Meeting
Differences in Histological Scores and Histoclinical Correlations in ACPA- Versus ACPA+ Rheumatoid Arthritis Patients
Fadil Pirbuccus¹, Christine Galant¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez² and Bernard R. Lauwerys¹, ¹Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Differences in the pathogenesis of ACPA- versus ACPA+ rheumatoid arthritis are still poorly understood. In this study, we compared patterns of synovial changes in…
Abstract Number: 3124 • 2016 ACR/ARHP Annual Meeting
Huntingtin Interacting Protein 1 (Hip1) Is a New Arthritis Severity Gene
Teresina Laragione¹, Percio Gulko¹ and Max Brenner², ¹Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Cia25/Pia42 is an arthritis severity and joint damage quantitative trait locus on rat chromosome 12 previously identified in an intercross between MHC identical but…
Abstract Number: 1210 • 2015 ACR/ARHP Annual Meeting
Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort
Jeffrey A. Sparks¹, Shun-Chiao Chang², Kevin D. Deane³, Ryan W. Gan⁴, Kristen Demoruelle³, Marie L. Feser³, LauraKay Moss³, Jane H. Buckner⁵, Richard M. Keating⁶, Karen H. Costenbader⁷, Peter K. Gregersen⁸, Michael H. Weisman⁹, Ted R. Mikuls¹⁰, James R. O'Dell¹⁰, V. Michael Holers³, Jill M. Norris⁴ and Elizabeth W. Karlson², ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Division of Rheumatology, Scripps Health, La Jolla, CA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁸Feinstein Insititute for Medical Research, Manhasset, NY, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Family history of RA in a first-degree relative increases RA risk 4-fold. Determining risk factors for inflammatory joint signs (IJS) in this high risk…
Abstract Number: 2582 • 2015 ACR/ARHP Annual Meeting
Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice
Richard Bell¹, Ronald Wood², Joe Chakkalakal³, Christopher T. Ritchlin⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Pathology, University of Rochester, Rochester, NY, ²University of Rochester, Rochester, NY, ³Orthopaedics, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating condition with a 2-3 fold greater prevalence in women than men. Additionally, women have worse disease outcomes…
Abstract Number: 1254 • 2015 ACR/ARHP Annual Meeting
Deciphering the Immunome of Clinically Effective Immune Tolerization in Rheumatoid Arthritis
Jing Yao Leong^1,2, Raymond Ong Jr.³, Juntao Li⁴, Theodorus van den Broek⁵, Roberto Spreafico⁴, Maura Rossetti¹ and Salvatore Albani^1,2, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ³Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁴SingHealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁵Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA
Background/Purpose: We have previously described (Nature Medicine, PNAS, A&R, Nature Rheum, Lancet) how oral treatment with the pro-inflammatory, heat shock protein-derived dnaJP1 peptide induces detectable…
Abstract Number: 2704 • 2015 ACR/ARHP Annual Meeting
Neutrophil-Derived Lactoferrin Regulates the Activity of NFAT5 in Rheumatoid Arthritis Synovial Fibroblasts Via Toll-like Receptor 4
Kunihiko Umekita, Shunichi Miyauchi, Kazuyoshi Kubo, Hajime Nomura, Kazumi Umeki, Koushou Iwao, Mao Komura and Akihiko Okayama, Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan
Background/Purpose: Damage-associated molecular patterns (DAMPs) are proposed to drive aberrant stimulation of Toll-like receptors (TLRs) in the rheumatoid arthritis (RA) joints resulting in increased expression…
Abstract Number: 1586 • 2015 ACR/ARHP Annual Meeting
Weight Loss in Obese Rheumatoid Arthritis (RA) Patients Improves Disease Activity without Modifying RA Treatment
Elisa Gremese¹, Maria Rita Gigante¹, Barbara Tolusso¹, Anna Laura Fedele¹, Silvia Canestri¹, Barbara Aquilanti², Clara Di Mario¹, Luca Petricca¹, Stefano Alivernini¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Dietology Service, Association Columbus, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Obesity is recognized as a systemic, low-grade inflammatory state and the adipose tissue as an endocrine organ releasing pro-inflammatory cytokines. On the other hand,…
Abstract Number: 2705 • 2015 ACR/ARHP Annual Meeting
AAA-Atpase p97-HDAC6 Controlled Poly-Ubiquitin Turnover Regulates Apoptotic and Autophagy-Associated Cell Death in Arthritis
Masaru Kato¹, Kerstin Klein², Caroline Ospelt², Christoph Kolling³, Michihito Kono¹, Shinsuke Yasuda¹, Renate E. Gay⁴, Steffen Gay⁵ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Schulthess Clinic, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland
Background/Purpose: The AAA-ATPase valosin containing protein (p97) and histone deacetylase 6 (HDAC6) interact with each other and are implicated in the degradation of ubiquitin-labelled proteins.…
Abstract Number: 1616 • 2015 ACR/ARHP Annual Meeting
Identification of Genes Regulating TRAIL-Induced Apoptosis in Rheumatoid Arthritis Fibroblasts-like Synoviocytes (RA FLS)
Rachel Audo^1,2, Bernard Combe^3,4, Michael Hahne⁵ and Jacques Morel⁶, ¹Rheumatology, Teaching Hospital of Lapeyronie, Montpellier, France, ²IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ³Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁴Montpellier University, Montpellier, France, ⁵IGMM-CNRS UMR5535, Montpellier, France, ⁶Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: We previously described that sensitivity to TRAIL-induced apoptosis varied in rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) from one patient to another, and was inversly correlated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].